×
Log in
Upload File
Most Popular
Study
Business
Design
Technology
Travel
Explore all categories
The top documents tagged [response duration]
[Day 2] Center Presentation: WFP
464 views
07 state of the art of the management of advanced and recurrent ovarian cancer
440 views
Dr. Gopichand Pendurti M.B.B.S ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT
213 views
Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine
219 views
Update: Non-Hodgkin’s Lymphoma 20082008. ICML 2008: Update on non-Hodgkin’s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients
229 views
FDA Review : Cisplatin / Epinephrine Gel (CEG) in the Treatment of Head and Neck Cancer
218 views
Steele Taylor presents: A Neuro-Endocrine Approach to The Obstetric and Pediatric Applications of Tactile-Kinesthetic Stimulation Therapy questions/complaints:
222 views
Differential Reinforcement & Differential Punishment Chapter 7
231 views
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent
214 views
STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab] Oncologic Drugs Advisory Committee December 17, 2002
214 views
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance
216 views
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi
232 views
Next >